Conditions: Lymphoma
Keywords: Refractory Indolent NHL lymphoma
Enrollment: 81
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.

Detailed description:

Arms:
arm 1: inotuzumab ozogamicin

Interventions: intervention 1: Inotuzumab Ozogamicin (CMC-544)
Intervention descriptions: intervention 1: Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles

Protocol document: